Skip to main content

Table 1 Characteristics of patients in PF group and TPF group before and after propensity score matching analysis

From: Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis

 

Before PSM

After PSM

Variables

PF group

[n (%), n = 425]

TPF group

[n (%), n = 177]

X2/Z

P

PF group

[n (%), n = 172]

TPF group

[n (%), n = 172]

X2/Z

P

Age (years) [median (IQR)]

61 (52~67)

58 (48~63)

−4.017a

<0.001

60 (51~64)

58 (48~63)

−1.399a

0.162

 < 65

271 (63.8)

141 (79.7)

14.618

< 0.001

130 (75.6)

136 (79.1)

0.597

0.440

 65~

154 (36.2)

36 (20.3)

42 (24.4)

36 (20.9)

Sex

  

0.383

0.536

  

0.234

0.628

 Male

313 (73.6)

126 (71.2)

  

127 (73.8)

123 (71.5)

  

 Female

112 (26.4)

51 (28.8)

  

45 (26.2)

49 (28.5)

  

Tumor location

  

2.348

0.125

  

0.187

0.665

 Cardia

214 (50.4)

77 (43.5)

  

81 (47.1)

77 (44.8)

  

 Non-cardia

211 (49.6)

100 (56.5)

  

91 (52.9)

95 (55.2)

  

Borrmann subtype

  

0.760

0.944

  

2.785

0.594

 I

13 (3.1)

5 (2.8)

  

7 (4.1)

5 (2.9)

  

 II

125 (29.4)

57 (32.2)

  

46 (26.7)

57 (33.1)

  

 III

241 (56.7)

94 (53.1)

  

101 (58.7)

90 (52.3)

  

 IV

26 (6.1)

12 (6.8)

  

12 (7.0)

11 (6.4)

  

 Unknown

20 (4.7)

9 (5.1)

  

6 (3.5)

9 (5.2)

  

Grade

  

1.452

0.484

  

1.356

0.508

 G1-2

111 (26.1)

38 (21.5)

  

41 (23.8)

37 (21.5)

  

 G3-4

285 (67.2)

126 (71.2)

  

113 (65.7)

122 (70.9)

  

 Unknown

29 (6.8)

13 (7.3)

  

18 (10.5)

13 (7.6)

  

T stage (AJCC 7th)

  

2.315

0.510

  

0.062

0.996

 T1

13 (3.1)

10 (5.6)

  

10 (5.8)

9 (5.2)

  

 T2

26 (6.1)

10 (5.6)

  

10 (5.8)

10 (5.8)

  

 T3

244 (57.4)

100 (56.5)

  

97 (56.4)

97 (56.4)

  

 T4

142 (33.4)

57 (32.2)

  

55 (32.0)

56 (32.6)

  

N stage (AJCC 7th)

  

4.149

0.246

  

2.971

0.396

 N0

86 (20.2)

25 (14.1)

  

33 (19.2)

25 (14.5)

  

 N1

80 (18.8)

42 (23.7)

  

30 (17.4)

41 (23.8)

  

 N2

113 (26.6)

50 (28.2)

  

54 (31.4)

50 (29.1)

  

 N3

146 (34.4)

60 (33.9)

  

55 (32.0)

56 (32.6)

  

Stage (AJCC 7th)

  

3.840

0.147

  

0.528

0.768

 I

17 (4.0)

12 (6.8)

  

11 (6.4)

11 (6.4)

  

 II

137 (32.2)

46 (26.0)

  

52 (30.2)

46 (26.7)

  

 III

271 (63.8)

119 (67.2)

  

109 (63.4)

115 (66.9)

  

Vascular invasion

  

1.899

0.168

  

0.134

0.714

 Yes

102 (24.0)

52 (29.4)

  

44 (25.6)

47 (27.3)

  

 No

323 (76.0)

125 (70.6)

  

128 (74.4)

125 (72.7)

  

Perineural invasion

  

0.001

0.979

  

0.091

0.763

 Yes

70 (16.5)

29 (16.4)

  

25 (14.5)

27 (15.7)

  

 No

355 (83.5)

148 (83.6)

  

147 (85.5)

145 (84.3)

  

Tumor deposits

  

1.546

0.214

  

0.595

0.441

 Positive

47 (11.1)

26 (14.7)

  

27 (15.7)

22 (12.8)

  

 Negative

378 (88.9)

151 (85.3)

  

145 (84.3)

150 (87.2)

  

Laparotomic approaches

  

0.454

0.500

  

0.000

1.000

 Open

384 (90.4)

163 (92.1)

  

158 (91.9)

158 (91.9)

  

 Laporascopy

41 (9.6)

14 (7.9)

  

14 (8.1)

14 (8.1)

  

Scope of gastrectomy

  

1.451

0.228

  

0.212

0.645

 Total gastrectomy

302 (71.1)

117 (66.1)

  

118 (68.6)

114 (66.3)

  

 Partial gastrectomy

123 (28.9)

60 (33.9)

  

54 (31.4)

58 (33.7)

  

 Hemoglobin (g/L) [median (IQR)]

111 (98~121)

115 (102~123)

1.647a

0.100

111 (98~120)

114 (102~123)

1.565a

0.118

 Albumin (g/L) [median (IQR)]

38.6 (35.6~41.9)

39.3 (36.0~42.7)

1.059a

0.290

38.0 (34.3~41.6)

39.2 (36.0~42.6)

1.776a

0.076

  1. aIndependent-samples Mann-Whitney U test
  2. PF, platinum plus fluoropyrimidines; TPF, taxanes, platinum plus fluoropyrimidines; PSM, propensity score matching analysis; IQR, inter quartile range. AJCC 7th, the seventh edition of cancer staging system by the American Joint Committee on Cancer